Furoscix Patent Expiration

Furoscix is a drug owned by Scpharmaceuticals Inc. It is protected by 3 US drug patents filed in 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 03, 2034. Details of Furoscix's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11433044 Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(9 years from now)

Active
US9884039 Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(9 years from now)

Active
US10272064 Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(9 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Furoscix's patents.

Given below is the list of recent legal activities going on the following patents of Furoscix.

Activity Date Patent Number
Patent litigations
Email Notification 21 Jan, 2023 US9884039
Mail Certificate of Correction Memo 20 Jan, 2023 US9884039
Certificate of Correction Memo 18 Jan, 2023 US9884039
Payment of Maintenance Fee, 4th Yr, Small Entity 31 Oct, 2022 US10272064
Patent Issue Date Used in PTA Calculation 06 Sep, 2022 US11433044
Recordation of Patent Grant Mailed 06 Sep, 2022 US11433044
Email Notification 18 Aug, 2022 US11433044
Issue Notification Mailed 17 Aug, 2022 US11433044
Dispatch to FDC 28 Jul, 2022 US11433044
Application Is Considered Ready for Issue 28 Jul, 2022 US11433044

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Furoscix is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Furoscix's family patents as well as insights into ongoing legal events on those patents.

Furoscix's Family Patents

Furoscix has patent protection in a total of 15 countries. It's US patent count contributes only to 25.0% of its total global patent coverage. Click below to unlock the full patent family tree for Furoscix.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Furoscix's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 03, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Furoscix Generics:

Furosemide is the generic name for the brand Furoscix. 29 different companies have already filed for the generic of Furoscix, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Furoscix's generic





About Furoscix

Furoscix is a drug owned by Scpharmaceuticals Inc. It is used for treating congestion due to fluid overload in adults with NYHA class II/III chronic heart failure. Furoscix uses Furosemide as an active ingredient. Furoscix was launched by Scpharmaceuticals in 2022.

Approval Date:

Furoscix was approved by FDA for market use on 07 October, 2022.

Active Ingredient:

Furoscix uses Furosemide as the active ingredient. Check out other Drugs and Companies using Furosemide ingredient

Treatment:

Furoscix is used for treating congestion due to fluid overload in adults with NYHA class II/III chronic heart failure.

Dosage:

Furoscix is available in solution form for subcutaneous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
80MG/10ML (8MG/ML) SOLUTION Prescription SUBCUTANEOUS